Osteopontin in cardiovascular disease: A potential therapeutic target

Alfonso H. Waller, Monica Sanchez Shields, Edo Kaluski, Marc Klapholz

Research output: Contribution to journalReview articlepeer-review

76 Scopus citations


Osteopontin (OPN), also known as 44kDa bone phosphoprotein, sialoprotein I, secreted phosphoprotein I, 2ar, uropontin, and early T-lymphocyte activation-1 (Eta-1), is a multifunctional protein. OPN has been found to be expressed in various cell types and species with many physiologic and pathologic functions. OPN has emerged as a potential biomarker and mediator in cardiovascular disease. In this review, we will discuss the roles of OPN in cardiovascular disease, specifically in vascular and valvular heart disease, myocardial infarction and heart failure.

Original languageEnglish (US)
Pages (from-to)125-131
Number of pages7
JournalCardiology in review
Issue number3
StatePublished - May 1 2010


  • Calcification
  • Heart failure
  • Myocardial infarction
  • Myocardial remodeling
  • Osteopontin
  • Valvular disease

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Osteopontin in cardiovascular disease: A potential therapeutic target'. Together they form a unique fingerprint.

Cite this